The United States is currently facing its most severe flu season since 2009, according to the latest data from the Centers for Disease Control and Prevention (CDC).TheCDChasclassifiedthisseasonas”highseverity” forallagegroups-markingthe first time a flu season has received this designation since 2017-18.
https://mma.prnewswire.com/media/2402201/Biolabs_logo.jpg
The 2024-25 influenza season has had a significant impact on public health, with the latestCDC Influenza Surveillance Report for the week ending February 8, 2025, revealing:
— 29 million flu-related illnesses
— 370,000 hospitalizations
— 16,000 deaths
Additionally, during the most recent reporting week, 31.6% of tested individuals were positiveforinfluenza,and50,382people werehospitalizedduetoflu-relatedcomplications.
BiolabsInternationalLLCExpands AccesstoRapidFlu&COVIDTesting Inresponsetothis critical public health challenge, Biolabs International LLC is proud to introduce its SpeedySwab™ Rapid COVID-19 + FLU A&B Antigen Self-Test, an at-home diagnostic solution designed to help detect and mitigate the spread of influenza and COVID-19.
Biolabs International has also redesigned its retail packaging to optimize in-store placement and visibility. The newly assembled-in-the-USA packaging is crafted for seamless integration into retail spaces, pharmacy shelves, and medical distribution networks.
“Our18-monthshelflifeprovidesanadditionalsixmonthsofusabilitycompared toother leading brands, making SpeedySwab™ the superior choice for families and healthcare providers during this challenging flu season,” said Gino Ajodani, President of Biolabs International LLC.
AI-PoweredDiagnostics:TheFutureofAt-HomeTesting
Biolabs International is also launching AI-integrated diagnostic solutions that enhance testingaccuracy andefficiency.These connecteddiagnostictoolsleveragereal-timedata management and artificial intelligence to streamline test result validation and improve decision-making.
“Thistechnologyrepresentsamajoradvancementinprecisiondiagnostics,”Ajodaniadded. “By seamlessly integrating AI, we empower consumers and healthcare professionals with faster, more reliable, and actionable insights-ensuring better health outcomes.”
CommitmenttoU.S.-BasedManufacturing&Supply ChainExpansion
As part of its ongoing commitment to domestic manufacturing and supply chain sustainability, BiolabsInternationalhasexpandeditsU.S.-basedoperationstosupport increasing demand for high-quality, reliable diagnostic solutions.
With SpeedySwab™ products now available through major retailers including Walgreens, Kroger,Ralphs,Amazon, andBevMo,Biolabs Internationalispoised forcontinuedgrowth throughout 2025.
AboutBiolabsInternationalLLC
BiolabsInternationalLLCistheexclusivedistributorofWatmindUSA™,manufacturerofthe SpeedySwab™ brand tests. This exclusivity spans across the United States, Mexico, Canada, South America, and Europe. Since the onset of the pandemic, Biolabs International LLC has been a leader in innovative diagnostic solutions, developing cutting-edge software and distributing rapid antigen tests through major retail and healthcare networks.
In partnership with SafeHealth Systems, BiolabsInternational has developed AI-powered healthcare applications, including telehealth-integrated testing solutions. The company continuestoexpand itsportfolio,withadditionalAI-drivenhealthcareinnovationssetfor release in early 2025.
Formediainquiries,please contact: Biolabs International LLC Info@biolabsinternational.net 800-440-4580
https://mma.prnewswire.com/media/2627663/Biolabs_International_Highly_Sensitive.jpg
https://mma.prnewswire.com/media/2627664/Biolabs_International_LLC_Rapid_Results.jpg
https://mma.prnewswire.com/media/2627665/Biolabs_International_LLC_app.jpg
https://c212.net/c/img/favicon.png?sn=LA27242&sd=2025-02-28
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolabs-international-llc-announces-its-successful-launch-of-speedyswab-rapid-covid-19–flu-ab-antigen-self-test-and-their-new-ai-driven-diagnostics-app-amid-the-most-severe-flu-season-since-2009-302387982.html
SOURCE Biolabs International LLC
https://rt.newswire.ca/rt.gif?NewsItemId=LA27242&Transmission_Id=202502280847PR_NEWS_USPR_____LA27242&DateId=20250228